Get to know our clinical trials
Clinical trial of relatlimab in combination with nivolumab and bevacizumab in previously untreated advanced/metastatic hepatocellular carcinoma
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE THE SAFETY AND EFFICACY OF RELATLIMAB COMBINED WITH NIVOLUMAB AND BEVACIZUMAB COMPARED TO THE COMBINATION OF NIVOLUMAB AND BEVACIZUMAB IN PATIENTS WITH LIVER CANCER.
Technical Summary
- PHASE I/II, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PLACEBO-CONTROLLED, CONFIRMATORY SAFETY STUDY OF RELATLIMAB IN COMBINATION WITH NIVOLUMAB AND BEVACIZUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC HEPATOCELLULAR CARCINOMA (RELATIVITY-106). IMMUNOTHERAPY
- Code EudraCT: 2021-003606-53
- Protocol number: CA224-106
- Promoter: Bristol Myers Squibb
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.